An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells.
An effective vaccine against colon cancer in mice: use of recombinant adenovirus interleukin-12 transduced dendritic cells.
复制标题
一种有效的小鼠结肠癌疫苗：使用重组腺病毒白介素 12 转导的树突状细胞。
DOI：
10.3748/wjg.14.532
复制
发表时间：
2008
影响因子：
4.3
通讯作者：
Yan
中科院分区：
文献类型：
--
作者：
Xiao;Liang Wang;Yan
目的
目的探讨重组腺病毒白细胞介素12（AdVIL-12）转导的树突状细胞（DCs）疫苗对小鼠结肠癌的治疗作用。
方法
DC和AdVIL-12以不同的时间间隔和不同的剂量一起孵育。收集上清液并通过酶联免疫吸附测定（ELISA）测试IL-12。为了确定肿瘤细胞裂解物脉冲的（TP）AdVIL-12/DC是否增强所建立的肿瘤模型中的治疗潜力，将CT 26结肠肿瘤细胞皮下（s.c.）在幼稚BALB/c小鼠的中胁腹中。在第3天和第10天，用CT 26 TP AdVIL-12/DC的疫苗接种荷瘤小鼠。作为保护性结肠肿瘤模型，将幼稚BALB/c小鼠皮下免疫。用CT 26 TP AdVIL-12/DC以7天的间隔两次在他们的小鼠中接种。第7天免疫后，用致死剂量的CT 26肿瘤细胞攻击小鼠，并评估存活时间。随后，在免疫小鼠中评价细胞毒性T淋巴细胞（CTL）活性和干扰素γ（IFN γ）分泌，并离体测定CTL。
结果
小鼠DCs经逆转录病毒转导后，分泌高水平的IL-12（AdVIL-12/DCs，615.27+/-42.3pg/mL vs DCs，46.32+/-7.29pg/mL，P<0.05）。接种CT 26 TP AdVIL-12/DCs可以增强小鼠治疗模型（第19天肿瘤体积：CT 26 TP AdVIL-12/DCs 107+/-42 mm 3 vs CT 26 TP DCs 383+/-65 mm 3，P<0.05）和保护模型中针对CT 26结肠肿瘤的抗肿瘤免疫力。此外，CT 26 TP AdVIL-12/DC疫苗接种增强了肿瘤特异性CTL活性，在免疫小鼠中产生高水平的IFN γ。体外用AdVIL-12/DC致敏的T细胞比用CT 26 TP/DC致敏的T细胞能够诱导更有效的CTL活性（E：T=100：1，69.49%+/-6.11%特异性裂解vs 37.44%+/-4.32%特异性裂解，P<0.05）。
结论
用重组AdVIL-12转导的DC脉冲的肿瘤细胞裂解物接种增强小鼠对结肠癌的特异性抗肿瘤免疫。
AIM
To investigate the effect of a vaccine with recombinant adenovirus interleukin-12 (AdVIL-12) transduced dendritic cells (DCs) against colon cancer in mice.
METHODS
DCs and AdVIL-12 were incubated together at different time intervals and at different doses. Supernatant was collected and tested for IL-12 by enzyme-linked immunosorbent assay (ELISA). In order to determine whether tumor cell lysate-pulsed (TP) AdVIL-12/DCs enhance therapeutic potential in the established tumor model, CT26 colon tumor cells were implanted subcutaneously (s.c.) in the midflank of naive BALB/c mice. Tumor-bearing mice were injected with a vaccination of CT26 TP AdVIL-12/DCs on d 3 and 10. As a protective colon tumor model, naive BALB/c mice were immunized s.c. in their abdomens with CT26 TP AdVIL-12/DCs twice at seven day intervals. After the immunization on d 7, the mice were challenged with a lethal dose of CT26 tumor cells and survival times were evaluated. Subsequently, cytotoxic T lymphocyte (CTL) activity and interferon gamma (IFNgamma) secretion was evaluated in the immunized mice, and assayed CTL ex vivo.
RESULTS
Murine DCs were retrovirally transduced with AdVIL-12 efficiency, and the AdVIL-12 transduced DCs secreted a high level of IL-12 (AdVIL-12/DCs, 615.27+/-42.3 pg/mL vs DCs, 46.32+/-7.29 pg/mL, P<0.05). Vaccination with CT26 TP AdVIL-12/DCs could enhance anti-tumor immunity against CT26 colon tumor in murine therapeutic models (tumor volume on d 19: CT26 TP AdVIL-12/DCs 107+/-42 mm3 vs CT26 TP DCs 383+/-65 mm3, P<0.05) and protective models. Moreover, the CT26 TP AdVIL-12/DC vaccination enhances tumor-specific CTL activity, producing high levels of IFNgamma in immunized mice. Ex vivo primed T cells with AdVIL-12/DCs were able to induce more effective CTL activity than in primed T cells with CT26 TP/DCs (E:T=100:1, 69.49%+/-6.11% specific lysis vs 37.44%+/-4.32% specific lysis, P<0.05).
CONCLUSION
Vaccination with recombinant AdVIL-12 transduced DC pulsed tumor cell lysate enhance anti-tumor immunity specific to colon cancer in mice.
登录
查看更多内容
影响因子：
--
作者：
D. Stone;A. Lieber
通讯作者：
D. Stone;A. Lieber
影响因子：
4.4
作者：
C. Tannenbaum;R. Tubbs;D. Armstrong;J. Finke;R. Bukowski;T. Hamilton
通讯作者：
C. Tannenbaum;R. Tubbs;D. Armstrong;J. Finke;R. Bukowski;T. Hamilton
DOI：
10.1172/jci10128
发表时间：
2001-07
期刊：
The Journal of clinical investigation
影响因子：
--
作者：
J. Wigginton;E. Gruys;L. Geiselhart;J. Subleski;K. Komschlies;J. Park;T. Wiltrout;K. Nagashima
通讯作者：
J. Wigginton;E. Gruys;L. Geiselhart;J. Subleski;K. Komschlies;J. Park;T. Wiltrout;K. Nagashima
人类树突状细胞经过基因工程改造，可表达高水平的人类上皮肿瘤抗原粘蛋白 (MUC-1)。
DOI：
--
发表时间：
1996
期刊：
Cancer research.
影响因子：
--
作者：
Henderson,RA;Nimgaonkar,MT;Watkins,SC;Robbins,PD;Ball,ED;Finn,OJ
通讯作者：
Finn,OJ